Insights
fact sheet
Comprehensive mRNA Solutions
Partner with Curia for combined expertise, speed and reliability to support the research, development and manufacturing of your mRNA product.
article
The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers
For many who are new to drug development, the greatest challenge is not necessarily discovering a blockbuster molecule—it’s finding a team capable of carrying that molecule through the complexities that lie between the research lab and the patien...
publications patents
A Year In Review — Curia's Contributions to Science in 2020
The following research articles appeared in peer-reviewed scientific journals that described innovations conceived by Curia scientists. In most of these cases, these manuscripts were written by Curia lead authors to communicate independent research...
white paper
The Shift Toward US Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix
The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) repor...
article
COVID-19: Updates from Curia
As the COVID-19 outbreak continues to spread across the globe, Curia is diligently monitoring the latest developments. As such, Curia has established a companywide taskforce to assure a coordinated response across our global network, focusing on em...
publications patents
Selected AMRI Publications and Patents from 2005–2019
Between 2005 and 2019, there have been over 350 published pieces and nearly 300 patents that AMRI has released.
publications patents
2019: A Year in Review — AMRI's Contributions to Science
The following research articles appeared in peer-reviewed scientific journals that described innovations conceived by AMRI scientists. In most of these cases, these manuscripts were written by AMRI lead authors to communicate independent research, or...